Meet Senzime at Arab Health in Dubai, 29th January – 1st February
Arab Health is the largest gathering of healthcare and trade professionals in the MENA region. The 2018 edition of the event is expected to welcome more than 4,200 exhibiting companies and 103,000 attendees from 150+ countries.
Senzime will be exhibiting our products in
the Swedish Pavilion, Za’abeel Hall 1, stand Z1.A50
"We are experiencing a large interest for our products from the MENA region. Participating at Arab Health gives us the opportunity to connect with different decision makers and distributors from the area visiting the show", says Catrin Molund, Business Development Director at Senzime.
For further information, please contact:
Catrin Molund, Business Development Director
Tel: +46-708-11 69 11,
TO THE EDITORS
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com